ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2653

Adventitial Fibroblast, an Important Actor in Giant Cell Arteritis

Simon Parreau1, Nicolas Vedrenne 2, Alexis Régent 3, Laurence Richard 4, Philippe Sindou 2, Luc Mouthon 3, Anne-Laure Fauchais 4, Marie-Odile Jauberteau 2 and Kim Heang Ly 1, 1Limoges University Hospital, Limoges, France, 2EA3842-CaPTuR, Limoges, 3National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, 4Limoges University Hospital, Limoges

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: giant cell arteritis and fibroblasts

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) is a systemic vasculitis affecting large vessels. The diagnosis is based on temporal artery biopsy (TAB) which shows an arterial infiltration accompanied by a destruction of the internal elastic layer of the media and a hyperplasia of the intima by proliferation of myofibroblasts. The origin of these myofibroblasts is controversial. Evidences suggest the activation of adventitial fibroblasts into myofibroblasts and their migration into the intima. The objective of this study was to determine whether adventitial fibroblasts migrate to the intima and thereby contribute to intimal hyperplasia during CGA.

Methods: Immunohistochemistry
Arterial sections from TAB of patients with GCA (n=24) and control subjects (n=24) were analyzed. Immunohistochemical analysis were performed using antibodies directed against fibroblasts (CD90, vimentin), myofibroblasts (alpha smooth muscle actin {ASMA}), vascular smooth muscle cells (desmin {VSMC}), prolyl-4-hydroxylase (collagen secretion activity {P4H}) and myosin (contraction activity). Stainings were quantified using ODPviewer® (Kamax Innovative System). Co-expression of CD90 with different stainings (ASMA, myosin and P4H) was also performed.  

Culture cells
TABs were dissected to separate the adventitia from the other two layers (media and intima). Each fragment was seeded separately. Cells were identified by immunocytochemistry. Functional assays were performed using culture cells obtained from GCA patients’ TABs (n=8) and controls (n=7): proliferation (bromodeoxyuridine incorporation test), migration (scratch test) and invasion (boyden chamber). Several conditions were used: i) DMEM-Glutamax alone, ii) addition of 10% fetal bovine serum (FBS), iii) addition of platelet-derived growth factor (PDGF) to 40 ng/mL, iv) supernatants of cells.

Results: CD90 and vimentin (fibroblasts) were significantly higher in GCA than controls in adventitia and intima. ASMA (myofibroblasts) was significantly higher in the 3 tunics of patients with GCA. Expression of desmin (VSMC) was only present in the media for both groups. The adventitial and intimal CD90+ cells co-expressed ASMA, P4H and myosin more importantly during GCA.

Cultured cells from adventitia expressed CD90 and did not express desmin. These adventitial cells had an increased in vitro proliferation ability during GCA compared to controls in the presence of FCS, PDGF and fibroblast supernatants of control or GCA patients. Migration and invasion rates of these cells were also significantly increased during GCA in the presence of FCS or PDGF.

Conclusion: Vascular remodeling during GCA would start in the adventitial layer with a key role of fibroblasts. Adventitial fibroblasts could be activated into myofibroblasts and acquire proliferative and migratory abilities. They would participate in the intimal hyperplasia. Finally, the activating signal of adventitial fibroblasts into myofibroblasts is not yet known during GCA and requires further studies.


Disclosure: S. Parreau, None; N. Vedrenne, None; A. Régent, None; L. Richard, None; P. Sindou, None; L. Mouthon, None; A. Fauchais, None; M. Jauberteau, None; K. Ly, None.

To cite this abstract in AMA style:

Parreau S, Vedrenne N, Régent A, Richard L, Sindou P, Mouthon L, Fauchais A, Jauberteau M, Ly K. Adventitial Fibroblast, an Important Actor in Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/adventitial-fibroblast-an-important-actor-in-giant-cell-arteritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adventitial-fibroblast-an-important-actor-in-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology